Lenox Catherine E, Lunn Katharine F
Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
J Am Vet Med Assoc. 2010 Jan 15;236(2):183-6. doi: 10.2460/javma.236.2.183.
To determine whether short-term administration of an oral glucosamine-chondroitin sulfate (Glu-CS) supplement alters serum fructosamine concentration in healthy dogs.
Prospective crossover study.
12 healthy adult dogs.
Dogs received Glu-CS and a placebo for 3 weeks each, with a 4-week minimum washout period between treatments. Serum fructosamine concentration was measured 4 times for each dog: prior to the first treatment period, at the end of the first treatment period, at the end of the washout period, and at the end of the second treatment period.
No significant change in serum fructosamine concentration was identified after treatment with either Glu-CS or the placebo. The change in serum fructosamine concentration associated with Glu-CS administration was not significantly different from the change in concentration associated with administration of the placebo.
Results suggest that in healthy dogs, short-term (ie, 21 days) oral Glu-CS administration does not affect glycemic control or cause diabetes mellitus.
确定短期口服氨基葡萄糖硫酸软骨素(Glu-CS)补充剂是否会改变健康犬的血清果糖胺浓度。
前瞻性交叉研究。
12只健康成年犬。
犬分别接受Glu-CS和安慰剂治疗3周,治疗期间至少有4周的洗脱期。每只犬测量4次血清果糖胺浓度:在第一个治疗期之前、第一个治疗期结束时、洗脱期结束时以及第二个治疗期结束时。
用Glu-CS或安慰剂治疗后,血清果糖胺浓度均未发现显著变化。与Glu-CS给药相关的血清果糖胺浓度变化与安慰剂给药相关的浓度变化无显著差异。
结果表明,在健康犬中,短期(即21天)口服Glu-CS不会影响血糖控制或导致糖尿病。